Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation

Abstract excerpt

Abstract Multiple myeloma (MM) is a plasma cell malignancy that is still considered to be incurable in most cases. A dominant mutation cluster has been identified in RAS/RAF genes, emphasizing the potential significance of RAS/RAF/MEK/ERK signaling as a therapeutic target. As yet, however, the clinical relevance of this finding is unclear as clinical responses to MEK inhibition in RAS -mutant MM have been mixed....